DrugPatentWatch Database Preview
ENLON-PLUS Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Enlon-plus patents expire, and when can generic versions of Enlon-plus launch?
Enlon-plus is a drug marketed by Mylan Institutional and is included in two NDAs.
The generic ingredient in ENLON-PLUS is atropine sulfate; edrophonium chloride. There are twenty-three drug master file entries for this compound. Additional details are available on the atropine sulfate; edrophonium chloride profile page.
Summary for ENLON-PLUS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Bulk Api Vendors: | 17 |
Patent Applications: | 2,530 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ENLON-PLUS at DailyMed |

Synonyms for ENLON-PLUS
(3-hydroxyphenyl)dimethylethylammonium |
116-38-1 (cloride) |
3-hydroxy-N,N-dimethyl-N-ethylanilinium |
312-48-1 |
70FP3JLY7N |
AB00053796 |
AB00053796_15 |
AC1L1FEK |
AC1Q7AIY |
AJ-08009 |
BC224295 |
BDBM120262 |
Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl- |
BPBio1_000008 |
BSPBio_000006 |
BSPBio_002386 |
C06976 |
C10H16NO.Cl |
CAS-116-38-1 |
CCG-204602 |
CHEBI:251408 |
CHEMBL1104 |
cid_8307 |
CJ-00045 |
Cyclopropanamine, 2-phenyl-, hydrochloride (1:1), (1S,2R)- |
DB01010 |
DivK1c_000809 |
DTXSID4046943 |
EDR |
Edrophone Chloride |
edrophonium |
Edrophonium Chloride, 3 |
EDROPHONIUM ION |
Edrophonum |
Edroponium |
Enlon |
Enlon Plus |
Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium |
ethyl-(3-hydroxyphenyl)-dimethylazanium |
GTPL9073 |
IDI1_000809 |
KBio1_000809 |
KBio2_000922 |
KBio2_003490 |
KBio2_006058 |
KBioGR_001032 |
KBioSS_000922 |
Lopac-E-3256 |
Lopac0_000511 |
LS-174330 |
MCULE-5963849469 |
N-ethyl-3-hydroxy-N,N-dimethylanilinium |
N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium |
NCGC00015409-01 |
NCGC00015409-02 |
NCGC00015409-03 |
NCGC00015409-04 |
NCGC00015409-05 |
NCGC00015409-06 |
NCGC00015409-07 |
NCGC00015409-08 |
NCGC00023975-03 |
NINDS_000809 |
Prestwick0_000083 |
Prestwick1_000083 |
Prestwick2_000083 |
Prestwick3_000083 |
Reversol |
SCHEMBL34790 |
SPBio_001220 |
SPBio_001945 |
Spectrum_000442 |
Spectrum2_001110 |
Spectrum4_000736 |
Spectrum5_001531 |
Tensilon |
UNII-70FP3JLY7N |
VWLHWLSRQJQWRG-UHFFFAOYSA-O |
ZINC1341 |
US Patents and Regulatory Information for ENLON-PLUS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Institutional | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Mylan Institutional | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019678-001 | Nov 6, 1991 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENLON-PLUS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan Institutional | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | Start Trial | Start Trial |
Mylan Institutional | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019678-001 | Nov 6, 1991 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |